Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists, which work by stimulating/activating/enhancing the r

Emerging in the landscape of weight management therapy, retatrutide is a distinct method. Beyond many existing medications, retatrutide functions as a dual agonist, simultaneously targeting both GLP peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) binding sites. The simultaneous activation fosters several beneficial effects, lik